3 min read

Free Webinar: Accelerating the antibody discovery workflow in the modern therapeutic landscape

4/9/20 9:15 AM

How can we access greater antibody diversity through the plasma B cell repertoire? How can we down-select lead candidates in 1 day? Join Abveris and Berkeley Lights for an exclusive webinar opportunity to learn how we're redefining the boundaries of antibody discovery with the Berkeley Lights Beacon platform.

Tuesday, April 14, 2020, 11 am EDT

View on-demand Webinar

As the complexity of therapeutic targets continues to evolve, more efficient and predictive identification of pertinent antibody candidates becomes increasingly valuable. Incorporating state-of-the-art, high-resolution discovery and antibody characterization tools like the Berkeley Lights platform into discovery workflows enables rapid and reliable selection of lead candidates more effectively than traditional techniques. Elucidating function early during screening and development can enhance candidate triage, as opposed to relying on brute-force methods to characterize large panels containing primarily non-functional clones. Optimization of the discovery platform using the Beacon instrument and case studies will be outlined.

Colby A. Souders, Ph.D., Chief Scientific Officer, Abveris

Colby holds a PhD in Cell and Molecular Biology from Texas A&M and has spent the last decade focused on antibody research. He first joined MassBiologics to lead discovery programs, develop platform technologies and advance monoclonal antibodies in the pipeline for the prevention, treatment or diagnosis of infectious and endogenous diseases. He later joined the Kanyos Bio Protein Engineering team to develop therapeutics based on a novel antigen-specific immune tolerance platform. In 2018 Colby joined Abveris Antibody with the goal as Chief Scientific Officer to usher in new antibody discovery tools and build a premium discovery engine.

Anupam Singhal, Ph.D., Product Manager, Antibody Therapeutics, Berkeley Lights

Anupam Singhal earned his PhD from the University of British Columbia and has over 15 years of experience in nanotechnology and microfluidics at UBC, the University of Toronto and Stanford University. His work has been cited over 600 times and resulted in several patents for molecular disease diagnosis, antibody discovery, and development of production cell-lines for biologics. At Berkeley Lights, Anupam leads the development of next-generation platforms for the discovery and development of antibody therapeutics.

View on-demand Webinar

Ryan Kelly

Written by Ryan Kelly

Associate Director of Business Development @ Abveris